Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2070428
Abstract: ABSTRACT Background Pharmacoeconomic studies comparing the cost of adalimumab biosimilars versus the originator and conventional drugs in psoriasis are lacking. Research design and methods To assess the cost per responder of adalimumab biosimilars versus the… read more here.
Keywords: cost per; responder; cost; adalimumab biosimilars ... See more keywords
Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia.
Sign Up to like & getrecommendations! Published in 2023 at "Expert opinion on biological therapy"
DOI: 10.1080/14712598.2023.2203812
Abstract: BACKGROUND Biosimilar adalimumabs have improved treatment access, but without any clinical advantage, distributors rely on delivery device design-enhancements, support services, and removal of painful excipients to capture market share. Prescribers, however, are often unaware of… read more here.
Keywords: originator versus; adalimumab biosimilars; versus adalimumab; adalimumab ... See more keywords
Riding the Wave of Adalimumab Biosimilars: Considerations for Pediatric Gastroenterologists
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Pediatric Gastroenterology and Nutrition"
DOI: 10.1097/mpg.0000000000003757
Abstract: In January of 2023, the first adalimumab biosimilar became available in the United States for treatment of inflammatory bowel disease (IBD). Seven more adalimumab biosimilars are set to become available over the summer and fall… read more here.
Keywords: biosimilars considerations; considerations pediatric; wave adalimumab; riding wave ... See more keywords